🟢 Strong Evidence
The World Health Organization prequalified a new artemether–lumefantrine formulation designed specifically for infants in April 2026, alongside three novel rapid diagnostic tests for malaria. The regulatory approvals represent a significant step toward simplifying treatment protocols in sub-Saharan Africa, where malaria mortality remains concentrated among children under five years old.
Key takeaways
- WHO prequalified the first artemether–lumefantrine formulation specifically formulated for infants in April 2026
- Three new rapid diagnostic tests were simultaneously prequalified, expanding diagnostic capacity in resource-limited settings
- The approvals address a critical gap in paediatric malaria treatment, where dosing and formulation constraints have limited options
- Prequalification enables procurement by UN agencies and opens market access for manufacturers in endemic countries
Regulatory Action at a Glance
| Regulatory body | World Health Organization |
| Action type | Prequalification of medicines and diagnostics |
| Products approved | 1 artemether–lumefantrine formulation (paediatric) + 3 rapid diagnostic tests |
| Target population | Infants and young children in malaria-endemic regions |
| Date | April 2026 |
WHO Prequalification Impact: Expanding Paediatric Malaria Tools
New products approved in April 2026, by type and availability pathway
Source: WHO Prequalification Unit, April 2026 | Georgian Medical Journal News
Closing a critical paediatric treatment gap
Malaria treatment in infants has long posed a clinical challenge. Standard artemether–lumefantrine formulations, while effective in older children and adults, are often difficult to dose accurately in infants due to their smaller body weight and pharmacokinetic differences. This new WHO-prequalified formulation addresses that gap directly, according to reporting by The Lancet Infectious Diseases (April 2026). The approval signals confidence in the product’s safety, efficacy, and quality standards, enabling purchase by the UN Children’s Fund (UNICEF), the Global Fund to Fight AIDS, Tuberculosis and Malaria, and other UN procurement mechanisms.
Prequalification is not a clinical recommendation but rather a regulatory pathway that certifies manufacturing standards and quality assurance. It does not imply that the product is superior to existing treatments—rather, it confirms that the product meets international standards for safety and efficacy. The WHO prequalification process typically involves submission of dossiers, laboratory testing, and inspection of manufacturing facilities.
Diagnostic capacity as the foundation of treatment access
The simultaneous prequalification of three rapid diagnostic tests reflects the reality that malaria treatment cannot be effective without accurate diagnosis. In many sub-Saharan African settings, parasitological confirmation remains limited by access to microscopy and polymerase chain reaction (PCR) testing. Rapid diagnostic tests provide point-of-care results within minutes, enabling treatment initiation at the community level. WHO’s Global Malaria Programme has prioritised diagnostic expansion as essential to the broader malaria elimination agenda, particularly in regions with high childhood mortality.
The three newly prequalified tests represent diverse manufacturers and geographies, which typically increases supply stability and competition-driven pricing. Prequalification creates a streamlined pathway for these products to reach procurement agents and national malaria control programmes in resource-limited settings.
Market dynamics and manufacturing incentives
WHO prequalification serves a dual regulatory function: it assures quality to purchasers and it opens markets for manufacturers. Manufacturers in endemic countries—particularly in India, Kenya, and other regional hub economies—have strong incentives to develop and prequalify new formulations and diagnostics, knowing that prequalification unlocks access to major procurement pathways. This encourages competition, which historically drives down prices and improves availability.
The artemether–lumefantrine combination remains one of the most widely used artemisinin-based combination therapies (ACTs) globally. Published efficacy data support its use, though emerging artemisinin resistance in Southeast Asia has prompted sustained research into next-generation ACTs. For sub-Saharan Africa, where malaria transmission remains high and resistance to artemether–lumefantrine is not yet widespread, this formulation addresses an immediate clinical need.
Implications for childhood malaria mortality
Malaria remains the leading cause of death in children under five in sub-Saharan Africa, according to WHO child health data. The introduction of an infant-specific artemether–lumefantrine formulation could streamline dosing, reduce administration errors, and improve treatment adherence by caregivers. However, prequalification alone does not guarantee uptake. National malaria programmes must integrate these products into treatment guidelines, health workers must be trained in their use, and supply chains must be secured. The Roll Back Malaria Partnership coordinates many of these efforts across endemic countries.
WHO prequalified an artemether–lumefantrine formulation specifically designed for infants and three rapid diagnostic tests in April 2026, expanding treatment options in sub-Saharan Africa where paediatric malaria burden remains highest.
— Sanjeet Bagcchi, reporting for The Lancet Infectious Diseases (April 2026)
What this means
Frequently asked questions
What does WHO prequalification mean?
WHO prequalification is a regulatory assessment that certifies a medicine or diagnostic has met international standards for quality, safety, and efficacy. It does not replace national regulatory approval but enables procurement by UN agencies and streamlines market access. Prequalification is based on dossier review, laboratory testing, and manufacturing site inspections conducted by WHO and partner agencies.
Why is an infant-specific artemether–lumefantrine formulation important?
Infants have different pharmacokinetics and smaller body weights than older children, making accurate dosing with standard formulations difficult and error-prone. A formulation designed for infants enables appropriate drug exposure and reduces the risk of underdosing or overdosing. This is particularly critical in settings where malaria mortality is highest.
Will these new products immediately reduce malaria deaths?
Prequalification is a necessary but not sufficient step. Uptake depends on integration into national treatment guidelines, health worker training, supply chain security, and affordability. Countries must implement these tools as part of comprehensive malaria control strategies that also include vector control, case management, and surveillance.
The prequalification of these products reflects sustained international commitment to expanding malaria treatment options in sub-Saharan Africa. However, malaria elimination remains a long-term goal requiring parallel investment in health system strengthening, surveillance, and vector control. Continued monitoring of efficacy and safety post-prequalification will be essential, particularly as resistance patterns evolve across endemic regions. Global health initiatives will need to coordinate with clinical guidelines updates to ensure these prequalified products reach patients who need them most.
Source: WHO prequalifications signal hope for malaria, Sanjeet Bagcchi, The Lancet Infectious Diseases, April 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
